Analysis and data insight

PwC focuses on how digital transformation in health care will impact consumers

December 30, 2019

Will the digital transformation in health care start to benefit consumers in 2020? That was one of the challenges addressed in a recent report from PwC Health Research Institute titled “Top health industry issues of 2020: Will digital start to show an ROI?” The report predicts that in the next year, health system leaders will tout their investments in technology and transformation.

Biggest gainers and losers for the week of Dec. 23-27, 2019

December 27, 2019

No Comments

The top 10 biopharma stock gainers and losers for the week.

Best of 'Word on the Street' part 2

Perspectives on the year: The industry has its say on scientific breakthroughs and ongoing policy sagas

December 27, 2019

By Peter Winter

No Comments

Throughout the year we have published the views of company executives, government regulators, industry analysts and scientists on a variety of topics and, in our popular annual feature, we include a selection of these that paints a picture of the significant events that shaped 2019.

Completed biopharmaceutical mergers & acquisitions: September 2019

December 27, 2019

No Comments

Completed biopharma mergers and acquisitions in September 2019.

Completed biopharmaceutical mergers & acquisitions: October 2019

December 27, 2019

No Comments

Completed biopharma mergers and acquisitions in October 2019.

Completed biopharmaceutical mergers & acquisitions: November 2019

December 27, 2019

No Comments

Completed biopharma mergers and acquisitions in November 2019.

Biopharmaceutical collaborations: November 2019

December 27, 2019

No Comments

Biopharma licensings, joint ventures and collaborations in November 2019.

Money raised by biopharma: 2019 vs. 2018

December 27, 2019

No Comments

Total raised in public, private and other financings of biopharma companies, comparing 2019 vs. 2018.

Biopharma money raised: Jan. 1-Dec. 20, 2019

December 27, 2019

No Comments

Year-to-date money raised in public, private and other financings of biopharma companies.

Best of 'Word on the Street' part 1

Perspectives on the year: The industry has its say on the markets, M&A and gene therapy

December 24, 2019

By Peter Winter

No Comments

Throughout the year we have published the views of company executives, government regulators, industry analysts and scientists on a variety of topics and, in our popular annual feature, we include a selection of these that paints a picture of the significant events that shaped 2019. The major talking point was on the capital markets front where investors turned their backs on the biopharmaceutical sector for most of the year returned big time in the final quarter.